Last reviewed · How we verify
NCT06053671: MosFED
Mos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue)
NA trial testing Blood and nasal swab sampling in Focal Cortical Dysplasia in 60 participants. Currently enrolling.
8 April 2025
Quick facts
| Lead sponsor | King's College Hospital NHS Trust |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 60 |
| Start date | 9 April 2023 |
| Primary completion | 8 April 2025 |
| Estimated completion | 8 April 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Blood and nasal swab sampling
Conditions studied
- Focal Cortical Dysplasia — all drugs for Focal Cortical Dysplasia →
- Epilepsy — all drugs for Epilepsy →
Sponsor
King's College Hospital NHS Trust
Who can join
Eligibility, any sex, with Focal Cortical Dysplasia or Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Focal cortical dysplasia (FCD) is a malformation of brain development, the most common cause of drug-resistant epilepsy and often caused by mutations in mammalian target of rapamycin (mTOR) pathway genes. Patients with FCD develop drug-resistant seizures. This study will look at FCD tissue removed during epilepsy surgery and aims to detect mutations in mTOR pathway genes in brain cells. Secondly, the investigators will establish if evidence of mutations found in brain cells can also be detected as circulating free DNA (cfDNA) in blood. By looking at which genes are made into proteins in individual cells found in epilepsy surgical tissue (single cell expression profiling),the investigators will attempt to identify new genetic targets in FCD. The main outcome will be finding new causes of epilepsy with FCD and the development of new diagnostic and screening tools.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06053671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood and nasal swab sampling
Trials testing the same drug.
- NCT05471011 — COVID-19 Outcome Prediction Algorithm · recruiting
Other King's College Hospital NHS Trust trials
Trials by the same sponsor.
- NCT07384884 — Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas · NA · not yet recruiting
- NCT07379723 — Brief Intervention for FCD: A Feasibility Study · NA · recruiting
- NCT07062731 — Pelvic Floor Exercises for Suboptimal Anorectal Manometry · recruiting
- NCT06766162 — Virtual Reality to Improve Patient Experience During Endoscopic Mucosal and Submucosal Resection · NA · completed
- NCT06918756 — Development of a Cough Control Questionnaire (CCQ) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06053671 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King's College Hospital NHS Trust
- Last refreshed: 23 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06053671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing